BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9.88
가격 · 8월 18, 2026
기준 재무 정보 8월 5, 2026
52주 범위
$6–$11
74% of range
애널리스트 평점
BUY
17 analysts
목표 주가
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
순이익률
30.2%
BioCryst Pharmaceuticals, Inc. - Common Stock 정보 위키백과 회사 개요
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
더 보기
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
BCRX 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$9.88
시가총액
$2.51B
P/E (TTM)
9.7
EPS (TTM)
$1.21
매출 (TTM)
$875M
배당 수익률
—
ROE
-97.6%
부채/자본
0.0
52주 범위
$6 – $11
BCRX 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
잉여현금흐름
$345M
2016-12-31
→
2025-12-31
마진
30.2%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
BCRX
동종업계 중앙값
P/E (TTM)
9.7
97.6
P/S (TTM)
2.9
7.7
P/B
-21.1
8.0
EV / EBITDA
6.5
—
Price / FCF (주가 / FCF)
7.3
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
BCRX
동종업계 중앙값
Operating Margin (영업이익률)
39.0%
—
Net Profit Margin (순이익률)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
BCRX
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
0.0
18.7
Current Ratio (유동비율)
2.1
4.9
Quick Ratio (당좌 비율)
1.9
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
BCRX
동종업계 중앙값
Revenue YoY (매출 YoY)
94.1%
—
Revenue CAGR 3Y (매출 CAGR 3년)
47.8%
—
Revenue CAGR 5Y (매출 CAGR 5년)
117.9%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
BCRX
동종업계 중앙값
BCRX 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
17 명의 애널리스트
- 적극 매수 5 29.4%
- 매수 10 58.8%
- 보유 2 11.8%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
11 명의 애널리스트 · 2026-08-17
중앙값
$17.00
평균
$20.82
← 모든 목표가 하회
$9.88
저가
$12.00
고가
$32.00
중앙값 목표
$17.00
+72.1%
평균 목표
$20.82
+110.7%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.02%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $0.30 | $0.12 | 0.18% |
| 2026년 3월 31일 | $-0.09 | $0.05 | -0.14% |
| 2025년 12월 31일 | $0.01 | $0.04 | -0.03% |
| 2025년 9월 30일 | $0.06 | $0.04 | 0.02% |
| 2025년 6월 30일 | $0.04 | $0.01 | 0.03% |
| 2025년 3월 31일 | $0.00 | $-0.07 | 0.07% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
대차대조표 27
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
현금 흐름 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 13
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
대차대조표 24
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
현금 흐름 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
유동성 및 지급능력 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
가치 평가 (TTM) 13
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $875M | $451M | $331M | $271M | $157M |
| 영업이익률 % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| 순이익 | $264M | $-89M | $-227M | $-247M | $-184M |
| 희석 EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| 유동비율 | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| 당좌 비율 | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $345M | $-53M | $-97M | $-163M | $-145M |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 346개의 제출자 · $2.1B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 63 (-7 이전 분기 대비) | 34 (-7 이전 분기 대비) | 130 (+19 이전 분기 대비) | 83 (+3 이전 분기 대비) | +25.9M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158,271,860 | 15,827,186 | 7.51% | 주식 |
| STATE STREET CORP | $151,910,980 | 15,191,098 | 7.21% | 주식 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150,964,030 | 15,096,403 | 7.16% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $113,642,360 | 11,364,236 | 5.39% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111,391,580 | 11,139,158 | 5.29% | 주식 |
| TCG Crossover Management, LLC | $110,209,680 | 11,020,968 | 5.23% | 주식 |
| PERCEPTIVE ADVISORS LLC | $103,088,880 | 10,308,888 | 4.89% | 주식 |
| JANUS HENDERSON GROUP PLC | $83,961,589 | 8,814,865 | 3.98% | 주식 |
| Vestal Point Capital, LP | $83,000,000 | 8,300,000 | 3.94% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $67,753,490 | 6,775,349 | 3.21% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $53,581,572 | 5,356,880 | 2.54% | 주식 |
| Aberdeen Group plc | $53,108,710 | 5,310,871 | 2.52% | 주식 |
| Frazier Life Sciences Management, L.P. | $40,092,400 | 4,009,240 | 1.90% | 주식 |
| GOLDMAN SACHS GROUP INC | $35,393,210 | 3,539,321 | 1.68% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $33,947,290 | 3,394,729 | 1.61% | 주식 |
| TWO SIGMA ADVISERS, LP | $31,895,074 | 4,089,112 | 1.51% | 주식 |
| RP Management, LLC | $28,846,155 | 3,846,154 | 1.37% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $27,161,110 | 2,716,111 | 1.29% | 주식 |
| Fisher Asset Management, LLC | $26,040,270 | 2,604,027 | 1.24% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $25,302,900 | 2,530,290 | 1.20% | 주식 |
| Kynam Capital Management, LP | $25,226,600 | 2,522,660 | 1.20% | 주식 |
| Candriam S.C.A. | $25,125,293 | 2,514,949 | 1.19% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23,532,910 | 2,353,291 | 1.12% | 주식 |
| RICE HALL JAMES & ASSOCIATES, LLC | $23,320,430 | 2,332,043 | 1.11% | 주식 |
| AQR CAPITAL MANAGEMENT LLC | $21,850,110 | 2,185,011 | 1.04% | 주식 |
| Nantahala Capital Management, LLC | $19,011,600 | 1,901,160 | 0.90% | 주식 |
| Eversept Partners, LP | $18,656,530 | 1,865,653 | 0.89% | 주식 |
| ORBIMED ADVISORS LLC | $18,520,000 | 1,852,000 | 0.88% | 주식 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18,449,120 | 1,844,912 | 0.88% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $17,595,730 | 1,759,573 | 0.83% | 주식 |
| CITADEL ADVISORS LLC | $17,591,600 | 1,759,160 | 0.83% | 주식 |
| IMC-Chicago, LLC | $16,343,360 | 1,634,336 | 0.78% | 주식 |
| Parkman Healthcare Partners LLC | $16,242,790 | 1,624,279 | 0.77% | 주식 |
| JANE STREET GROUP, LLC | $14,267,680 | 1,426,768 | 0.68% | 주식 |
| OP Asset Management Ltd | $13,409,900 | 1,340,990 | 0.64% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11,956,510 | 1,195,651 | 0.57% | 주식 |
| Pictet Asset Management Holding SA | $11,951,392 | 1,249,771 | 0.57% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $11,740,520 | 1,174,052 | 0.56% | 주식 |
| FIRST TRUST ADVISORS LP | $11,204,690 | 1,120,469 | 0.53% | 주식 |
| JANE STREET GROUP, LLC | $9,944,130 | 994,413 | 0.47% | 콜 옵션 |
| Cubist Systematic Strategies, LLC | $9,462,419 | 1,246,696 | 0.45% | 주식 |
| MOORE CAPITAL MANAGEMENT, LP | $8,483,360 | 848,336 | 0.40% | 주식 |
| FMR LLC | $8,062,330 | 806,233 | 0.38% | 주식 |
| BANK OF AMERICA CORP /DE/ | $7,754,020 | 775,402 | 0.37% | 주식 |
| ExodusPoint Capital Management, LP | $7,449,170 | 744,917 | 0.35% | 주식 |
| Man Group plc | $7,324,800 | 732,480 | 0.35% | 주식 |
| Rosalind Advisors, Inc. | $7,215,040 | 721,504 | 0.34% | 주식 |
| Schonfeld Strategic Advisors LLC | $7,108,160 | 710,816 | 0.34% | 주식 |
| BlackRock, Inc. | $5,984,400 | 598,440 | 0.28% | 주식 |
| Elmind Capital, LP | $5,200,000 | 520,000 | 0.25% | 주식 |
| Bridgewater Associates, LP | $4,910,570 | 491,057 | 0.23% | 주식 |
| NAN FUNG TRINITY (HK) LTD | $4,500,000 | 450,000 | 0.21% | 주식 |
| SPHERA FUNDS MANAGEMENT LTD. | $4,220,510 | 422,051 | 0.20% | 주식 |
| Swiss National Bank | $4,152,680 | 415,268 | 0.20% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $4,047,040 | 404,704 | 0.19% | 주식 |
| DAFNA Capital Management LLC | $4,002,480 | 400,248 | 0.19% | 주식 |
| Hudson Bay Capital Management LP | $4,000,000 | 400,000 | 0.19% | 주식 |
| Aquatic Capital Management LLC | $3,628,950 | 362,895 | 0.17% | 주식 |
| DOLIVER CAPITAL ADVISORS, INC. | $3,563,603 | 374,328 | 0.17% | 주식 |
| Assenagon Asset Management S.A. | $3,530,440 | 353,044 | 0.17% | 주식 |
| Kodai Capital Management LP | $3,515,993 | 468,799 | 0.17% | 주식 |
| MACKENZIE FINANCIAL CORP | $3,472,990 | 347,299 | 0.16% | 주식 |
| CITIGROUP INC | $3,467,520 | 346,752 | 0.16% | 주식 |
| Phocas Financial Corp. | $3,405,410 | 340,541 | 0.16% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3,238,000 | 323,800 | 0.15% | 콜 옵션 |
| ALPS ADVISORS INC | $3,179,600 | 317,960 | 0.15% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $3,121,694 | 327,909 | 0.15% | 주식 |
| RHUMBLINE ADVISERS | $2,798,390 | 279,839 | 0.13% | 주식 |
| Rafferty Asset Management, LLC | $2,656,180 | 265,618 | 0.13% | 주식 |
| Point72 Asset Management, L.P. | $2,609,170 | 260,917 | 0.12% | 주식 |
| Nuveen, LLC | $2,599,030 | 259,903 | 0.12% | 주식 |
| NFJ INVESTMENT GROUP, LLC | $2,568,330 | 256,833 | 0.12% | 주식 |
| Nebula Research & Development LLC | $2,567,121 | 286,509 | 0.12% | 주식 |
| WINTON GROUP Ltd | $2,556,000 | 255,600 | 0.12% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2,459,444 | 258,345 | 0.12% | 주식 |
| MARTINGALE ASSET MANAGEMENT L P | $2,425,080 | 242,508 | 0.12% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $2,324,670 | 232,467 | 0.11% | 주식 |
| CITADEL ADVISORS LLC | $2,322,000 | 232,200 | 0.11% | 콜 옵션 |
| IEQ CAPITAL, LLC | $2,274,210 | 227,421 | 0.11% | 주식 |
| Bank of New York Mellon Corp | $2,251,670 | 225,167 | 0.11% | 주식 |
| D. E. Shaw & Co., Inc. | $2,249,120 | 224,912 | 0.11% | 주식 |
| JUPITER ASSET MANAGEMENT LTD | $2,221,030 | 222,103 | 0.11% | 주식 |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2,100,000 | 210,000 | 0.10% | 주식 |
| PFM Health Sciences, LP | $2,073,570 | 207,357 | 0.10% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $1,962,800 | 196,280 | 0.09% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $1,951,280 | 195,128 | 0.09% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,853,000 | 185,300 | 0.09% | 풋 옵션 |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1,820,161 | 233,354 | 0.09% | 주식 |
| Engineers Gate Manager LP | $1,750,020 | 175,002 | 0.08% | 주식 |
| Squarepoint Ops LLC | $1,747,140 | 174,714 | 0.08% | 주식 |
| QTR Family Wealth, LLC | $1,610,820 | 161,082 | 0.08% | 주식 |
| Gotham Asset Management, LLC | $1,564,210 | 156,421 | 0.07% | 주식 |
| CITADEL ADVISORS LLC | $1,450,000 | 145,000 | 0.07% | 풋 옵션 |
| Corient Private Wealth LP | $1,429,860 | 142,986 | 0.07% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $1,386,570 | 138,657 | 0.07% | 주식 |
| Quantinno Capital Management LP | $1,374,530 | 137,453 | 0.07% | 주식 |
| MetLife Investment Management, LLC | $1,356,700 | 135,670 | 0.06% | 주식 |
| PROFUND ADVISORS LLC | $1,340,340 | 134,034 | 0.06% | 주식 |
| Virtus Investment Advisers, LLC | $1,336,640 | 133,664 | 0.06% | 주식 |
| ADAR1 Capital Management, LLC | $1,330,000 | 133,000 | 0.06% | 주식 |
회사 내부자 51 명의 내부자 · 21 임원 · 30 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 2025년 12월 17일 A | 268,700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 2024년 12월 19일 A | 377,867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 2020년 2월 21일 A | 125,176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 2011년 3월 16일 M | 57,102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 2025년 12월 22일 M | 952,583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 2008년 3월 14일 A | 65,730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 2026년 5월 13일 M | 400,703 | 0 | 7 | $-3,461,969 |
| Sandeep Menon | Chief R&D Officer | 2026년 4월 6일 A | 205,150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 2025년 3월 31일 F | 377,318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 2022년 12월 19일 A | 16,653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 2022년 11월 14일 M | 298,541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 2022년 3월 10일 M | 37,954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 2020년 12월 15일 A | 45,000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 2019년 1월 28일 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 2012년 3월 15일 F | 24,124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 2011년 2월 7일 A | 9,766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 2010년 3월 12일 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 2008년 7월 31일 P | 3,048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 2007년 7월 31일 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 2007년 7월 31일 P | 3,659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 2007년 5월 16일 A | 1,928 | 0 | 0 | $0 |
| Amy E Mckee | 이사 | 2026년 6월 11일 A | 47,177 | 0 | 1 | $-100,285 |
| Theresa Heggie | 이사 | 2026년 6월 11일 A | 80,646 | 0 | 1 | $-504,823 |
| Machelle Sanders | 이사 | 2026년 6월 11일 A | 45,936 | 0 | 1 | $-68,544 |
| Jill C. Milne | 이사 | 2026년 6월 11일 A | 31,938 | 0 | 0 | $0 |
| Steven Frank | 이사 | 2026년 6월 11일 A | 35,459 | 0 | 0 | $0 |
| Steven K Galson | 이사 | 2026년 6월 11일 A | 27,794 | 0 | 0 | $0 |
| Jon P Stonehouse | 이사 | 2026년 6월 11일 A | 1,339,775 | 0 | 0 | $0 |
| Vincent Milano | 이사 | 2026년 6월 11일 A | 108,483 | 0 | 0 | $0 |
| Alan G Levin | 이사 | 2026년 6월 11일 A | 79,565 | 0 | 0 | $0 |
| Nancy J Hutson | 이사 | 2025년 6월 12일 A | 99,138 | 0 | 0 | $0 |
| George B Abercrombie | 이사 | 2024년 6월 12일 A | 36,431 | 0 | 0 | $0 |
| Steve Aselage | 이사 | 2024년 6월 12일 A | 70,159 | 0 | 0 | $0 |
| Kenneth B Lee JR | 이사 | 2023년 6월 13일 A | 68,863 | 0 | 0 | $0 |
| Robert Alexander Ingram | 이사 | 2023년 2월 28일 A | 100,198 | 0 | 0 | $0 |
| Stanley C Erck | 이사 | 2018년 11월 28일 M | 48,333 | 0 | 0 | $0 |
| Fred Cohen | 이사 | 2018년 6월 20일 A | 119,410 | 0 | 0 | $0 |
| Sanj K Patel | 이사 | 2017년 5월 24일 A | — | 0 | 0 | $0 |
| Charles A Sanders | 이사 | 2016년 2월 29일 A | 12,971 | 0 | 0 | $0 |
| Peder Jensen | 이사 | 2014년 5월 2일 A | 60,000 | 0 | 0 | $0 |
| John L Higgins | 이사 | 2012년 5월 23일 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | 이사 | 2012년 5월 23일 A | 3,000 | 0 | 0 | $0 |
| Stephen R Biggar | 이사 | 2011년 5월 12일 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | 이사 | 2010년 5월 13일 A | 3,000 | 0 | 0 | $0 |
| William W Featheringill | 이사 | 2010년 5월 13일 A | 231,538 | 0 | 0 | $0 |
| William M Spencer III | 이사 | 2007년 5월 16일 A | 186,761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | 이사 | 2007년 5월 16일 A | 451,900 | 0 | 0 | $0 |
| Charles E Bugg | 이사 | 2007년 3월 18일 A | 62,439 | 0 | 0 | $0 |
| GORDON CARL L | 이사 | 2006년 5월 17일 A | 1,100,000 | 0 | 0 | $0 |
| John A Montgomery | 이사 | 2003년 11월 4일 M | 46,785 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 15 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 제출 서류 | 2018년 7월 31일 | — | 최초 제출 | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2018년 4월 2일 | — | 최초 제출 | 수동적 투자 | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 제출 서류 | 2016년 8월 16일 | — | 최초 제출 | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 제출 서류 | 2012년 10월 23일 | — | 최초 제출 | M&A / 매각 | SEC |
| Julian C. Baker, Felix J. Baker ×4 제출 서류 | 2011년 10월 13일 | — | 최초 제출 | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 제출 서류 | 2007년 8월 20일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2005년 12월 7일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2005년 12월 7일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2005년 12월 7일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2005년 10월 13일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2004년 2월 26일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2004년 2월 25일 | — | 최초 제출 | — | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2004년 2월 24일 | — | 최초 제출 | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 제출 서류 | 2003년 10월 31일 | — | 최초 제출 | — | SEC |
| William W. Featheringill | 2002년 2월 14일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 53 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2.65% | 1,023,838 SH | 2026년 8월 8일 | 일간 |
| BBP · ETFis Series Trust I | 1.93% | 125,015 NS | 2026년 4월 30일 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1.26% | 1,682 NS | 2026년 4월 30일 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.67% | 381,305 NS | 2026년 4월 30일 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.54% | 612,341 NS | 2026년 4월 30일 | N-PORT |
| CALF · Pacer Funds Trust | 0.41% | 1,556,494 NS | 2026년 4월 30일 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.28% | 364,624 NS | 2026년 4월 30일 | N-PORT |
| BFOR · ALPS ETF Trust | 0.25% | 59,894 NS | 2026년 5월 31일 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.24% | 72,535 SH | 2026년 8월 8일 | 일간 |
| GSSC · Goldman Sachs ETF Trust | 0.19% | 213,133 NS | 2026년 5월 31일 | N-PORT |
| SMLF · iShares Trust | 0.17% | 758,958 SH | 2026년 8월 8일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.16% | 13,830 SH | 2026년 8월 8일 | 일간 |
| IBB · iShares Trust | 0.15% | 1,580,105 SH | 2026년 8월 8일 | 일간 |
| ESSC · Strategy Shares | 0.15% | 4,183 NS | 2026년 4월 30일 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.14% | 249,665 SH | 2026년 8월 8일 | 일간 |
| IWO · iShares Trust | 0.13% | 2,097,061 SH | 2026년 8월 8일 | 일간 |
| BIB · ProShares Trust | 0.11% | 9,271 NS | 2026년 5월 31일 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.11% | 57,134 NS | 2026년 4월 30일 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.10% | 81,871 NS | 2026년 4월 30일 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 1,339,774 SH | 2026년 8월 8일 | 일간 |
| ISCG · iShares Trust | 0.07% | 73,787 SH | 2026년 8월 8일 | 일간 |
| IWM · iShares Trust | 0.07% | 5,925,076 SH | 2026년 8월 8일 | 일간 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.07% | 206,325 SH | 2026년 8월 8일 | 일간 |
| RSSL · Global X Funds | 0.06% | 97,958 NS | 2026년 4월 30일 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 806,097 NS | 2026년 4월 30일 | N-PORT |
| ITWO · ProShares Trust | 0.05% | 10,652 NS | 2026년 5월 31일 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.05% | 1,154,262 NS | 2026년 5월 31일 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.04% | 1,696,014 SH | 2026년 8월 8일 | 일간 |
| ISCB · iShares Trust | 0.03% | 10,494 SH | 2026년 8월 8일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 96,151 NS | 2026년 4월 30일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2,837,341 SH | 2026년 8월 8일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.03% | 624,412 SH | 2026년 8월 8일 | 일간 |
| UWM · ProShares Trust | 0.03% | 8,331 NS | 2026년 5월 31일 | N-PORT |
| URTY · ProShares Trust | 0.02% | 8,425 NS | 2026년 5월 31일 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.02% | 2,922,024 SH | 2026년 8월 8일 | 일간 |
| WSML · iShares Trust | 0.02% | 11,689 SH | 2026년 8월 8일 | 일간 |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 9,529 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.01% | 212 NS | 2026년 5월 31일 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 80,493 NS | 2026년 5월 31일 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 74,317 NS | 2026년 4월 30일 | N-PORT |
| IWV · iShares Trust | 0.00% | 72,218 SH | 2026년 8월 8일 | 일간 |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.00% | 937 NS | 2026년 5월 31일 | N-PORT |
| ITOT · iShares Trust | 0.00% | 336,352 SH | 2026년 8월 8일 | 일간 |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 141,645 NS | 2026년 5월 31일 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 6,314 NS | 2026년 4월 30일 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 34,873 NS | 2026년 4월 30일 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.00% | 8,956 NS | 2026년 4월 30일 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.00% | 129 NS | 2026년 5월 31일 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 3,019 NS | 2026년 4월 30일 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 8,070,274 SH | 2026년 8월 8일 | 일간 |